Published in J Clin Oncol on June 08, 2009
Management of thymic tumors: a European perspective. J Thorac Dis (2014) 0.87
Thymoma-associated paraneoplastic polymyositis. J Clin Oncol (2010) 0.79
Choroidal metastases from thymic carcinoma during pregnancy: Case Report. BMC Cancer (2015) 0.75
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 4.39
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol (2008) 3.43
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15
Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A (2006) 3.11
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res (2002) 2.81
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res (2010) 2.44
LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 2.28
Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res (2009) 2.07
Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics (2008) 1.95
Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91
Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol (2010) 1.86
Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol (2004) 1.76
Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer (2005) 1.73
Maintenance chemotherapy in non-small cell lung cancer. J Natl Compr Canc Netw (2010) 1.48
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42
Transcriptomes of human prostate cells. BMC Genomics (2006) 1.42
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis (2007) 1.41
Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy. Clin Cancer Res (2012) 1.41
Characterization of prostate cell types by CD cell surface molecules. Am J Pathol (2002) 1.38
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol (2011) 1.33
Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res (2008) 1.32
Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg (2008) 1.28
Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol (2007) 1.26
Development of the Minimum Information Specification for In Situ Hybridization and Immunohistochemistry Experiments (MISFISHIE). OMICS (2006) 1.26
Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol (2008) 1.23
Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate (2003) 1.22
Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes. BMC Cancer (2009) 1.19
Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer (2009) 1.15
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol (2013) 1.14
Stromal mesenchyme cell genes of the human prostate and bladder. BMC Urol (2005) 1.13
Medullary thyroid cancer: options for systemic therapy of metastatic disease? J Clin Oncol (2006) 1.10
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer (2003) 1.10
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res (2010) 1.09
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res (2009) 1.08
Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol (2007) 1.08
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res (2010) 1.07
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res (2013) 1.07
Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol (2007) 1.02
Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev (2005) 1.02
The urologic epithelial stem cell database (UESC) - a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladder. BMC Urol (2007) 1.02
Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care (2008) 1.01
Metastases of prostate cancer express estrogen receptor-beta. Urology (2004) 1.01
Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res (2007) 1.00
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate (2010) 0.96
Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine. Prostate (2011) 0.95
Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate (2007) 0.94
Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int J Cancer (2005) 0.94
Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res (2004) 0.93
Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int J Cancer (2003) 0.91
Multicolor multicycle molecular profiling with quantum dots for single-cell analysis. Nat Protoc (2013) 0.91
Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol (2013) 0.90
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol (2013) 0.90
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate (2013) 0.89
Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate (2010) 0.89
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics (2011) 0.89
WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res (2008) 0.88
Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol (2013) 0.88
Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. Clin Cancer Res (2007) 0.87
Fibroblast growth factor-10 signals development of von Brunn's nests in the exstrophic bladder. Am J Physiol Renal Physiol (2010) 0.87
Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis. Prostate (2009) 0.86
Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes. Cell Tissue Res (2012) 0.86
Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium. Genomics (2003) 0.84
Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. Am J Clin Pathol (2010) 0.83
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res (2007) 0.83
Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res (2008) 0.83
Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res (2009) 0.83
Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. Transl Oncol (2009) 0.82
Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol (2005) 0.82
Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia. Am J Hematol (2003) 0.81
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2010) 0.81
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer (2012) 0.81
Differential Inductive Signaling of CD90 Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells. Cancer Microenviron (2011) 0.80
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication. J Thorac Oncol (2015) 0.79
The role of chemotherapy in the management of stage IIIA non-small cell lung cancer. Am Soc Clin Oncol Educ Book (2013) 0.79
On the use of quantitative modeling to help understand prostate-specific antigen dynamics and other medical problems. Am J Clin Pathol (2003) 0.79
Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma. Exp Mol Pathol (2012) 0.79
Multifaceted genitourinary lymphoma. Curr Probl Diagn Radiol (2008) 0.79
Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: a case report and review of the literature. Head Neck (2012) 0.79
Flow cytometry analysis of proliferative lesions at the gastrocystoplasty anastomosis. J Urol (2003) 0.78
18F FDG-PET/CT findings in recurrent respiratory papillomatosis. Ann Nucl Med (2008) 0.78
Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma. J Urol (2007) 0.78
How wide is the spectrum of neuroendocrine carcinoma of the urinary bladder? Am J Clin Pathol (2007) 0.78
Prostate-specific antigen: a clinical and mathematical conundrum. Am J Clin Pathol (2006) 0.77
The time for accurate Fuhrman grading of renal cell carcinomas has arrived. Am J Clin Pathol (2002) 0.77
The role of tissue microarrays in prostate cancer biomarker discovery. Adv Anat Pathol (2007) 0.77
Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices. Adv Urol (2013) 0.75
Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence. Am J Surg Pathol (2014) 0.75
Endothelial cells in B-cell lymphomas. N Engl J Med (2004) 0.75
Response to paclitaxel in adenoid cystic carcinoma of the salivary glands. Head Neck (2008) 0.75
Report of a sphenoid sinus lipoma. Ear Nose Throat J (2012) 0.75